Marketing-Börse PLUS - Fachbeiträge zu Marketing und Digitalisierung
print logo

PharmSource - Bio/Pharma CapEx Market Research Report & Industry Analysis

provides an overview of Global Top Countries PharmSource-Bio/ Pharma CapEx 2016 Market Research Synopsis with inputs from industry experts
Rashmi Saraf | 04.01.2017
©
Description

Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry. Based on recent capital expenditure trends, it’s clear that bio/pharma companies would rather “make than buy.”

According to the latest PharmSource Trend Report, Bio/Pharma CapEx Trends 2016, bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years, an amount at least 10 times greater than what CMOs have invested in themselves. Global and generic bio/pharma companies, in particular, have invested heavily in new capacity, especially for biopharmaceuticals and in emerging markets.

Request a sample of this report @ http://orbisresearch.com/contacts/request-sample/163277

Scope

- Bio/Pharma CapEx Trends 2016 analyzes recent trends in capital spending by bio/pharma companies and assesses the implications for the CMO industry.
- It tracks spending by major segments of the bio/pharma industry, with detailed information on investments by global and generic biopharma companies.
- It discusses the outlook for the next five years, analyzes why major bio/pharma companies continue to favor captive capacity and describes the continuing role of CMOs in the bio/pharma supply chain.

Purchase a copy of PharmSource - Bio/Pharma CapEx Trends 2016 Report Visit: http://orbisresearch.com/contact/purchase/163277


Reasons to buy

- The 16-page report provides important insight that you won’t find in any other source. This report is required reading for -
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.

Some Points From TOC:

List of Tables
Table 1 Composition of the PharmSource Universe
Table 2 Analysis of Identified CapEx Projects
Table 3 Location of Identified CapEx Projects

List of Figures
Figure 1 CapEx by Company Sector 2015
Figure 2 Comparison of CapEx Change to Revenue Change 2010-2015
Figure 3 CapEx Trends at Bio/Pharma Companies 2010-2015
Figure 4 CapEx Spend and Growth Rate for Global Bio/Pharma Companies
Figure 5 Cash Spent on Dividends, Share Repurchase and CapEx by Selected US Global Bio/Pharma Companies 2010-2015
Figure 6 Capital Expenditure for Leading Public CDMOs